Answers are grounded in this paper and cite their sources.
Adult T-cell leukemia (ATL) is an aggressive CD4+ T-cell malignancy caused by the oncogenic retrovirus human T-cell leukemia virus-1 (HTLV-1). 1 Although the cumulative incidence of ATL among HTLV-1-infected individuals is only 5%, it has an extremely poor prognosis and remains a major health concern in endemic regions. 2 , 3 Patients with an aggressive subtype have a median survival of 4–6 and 9–10 months for acute and lymphoma subtypes, respectively (Shimoyama classification 4 ). Indolent forms (chronic and smoldering) have a more favorable median survival of 33 and 51 months. Treatment strategies for ATL mainly depend on clinical subtype, geographical localization and response to initial therapy. 5 , 6 In Japan, aggressive forms are treated by conventional chemotherapy combined or not with allogeneic stem cell transplantation, 7 while in western countries the combination of zidovudine (AZT) with interferon (IFN) alpha is the standard first-line therapy for acute leukemic subtypes and chronic forms. 6 Response to treatment and complete clinical remission are currently defined on the basis of cytomorphological consensus criteria that have not been revised over the 8 years since they were first described 8 ( Supplementary Methods ). Given the extremely poor prognosis of ATL, the high rates of rapid relapse and the marked diversity in survival outcome after achieving hematological remission, there is an urgent need for new molecular tools that can reliably evaluate therapeutic response and better define remission.
No takes yet. Share an insight, caveat, or question.
Artesi et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: